SonoVascular

Executive Summary

SonoVascular is a private medical device company developing the SonoThrombectomy™ System, an innovative ultrasound-based catheter for treating venous thromboembolism (VTE), specifically deep vein thrombosis (DVT). The device uses microbubble-mediated cavitation to mechanically debulk clots in a single session, aiming to reduce the risk of post-thrombotic syndrome (PTS) more effectively than current standard of care (anticoagulation and compression). Unlike existing thrombectomy devices that rely on aspiration or pharmacological lysis, SonoThrombectomy leverages low-frequency ultrasound to generate cavitation bubbles that disrupt clot structure, potentially offering superior safety and efficacy while lowering procedure costs. The company is targeting a large unmet need: approximately 900,000 DVT cases annually in the U.S., with a significant proportion developing PTS despite guideline-directed therapy. While SonoVascular remains in the development stage, its technology has attracted attention for its ability to provide a rapid, minimally invasive, and complete clot removal without the bleeding risks associated with thrombolytics. The company's progress through clinical validation and regulatory pathways will be critical to its commercialization.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial results60% success
• Q2 2026FDA breakthrough device designation70% success
• Q4 2026Series B or strategic partnership funding round55% success